Eun-Jung Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eun-Jung Choi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Cheol Min Lee
Department of Internal Medicine, Pusan National University School of Medicine, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea
3 shared publications - Cheol Woong Choi
Department of Internal Medicine, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea
3 shared publications - Dae Gon Ryu
Department of Internal Medicine, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea
3 shared publications - Jin Ook Jang
Department of Internal Medicine, Pusan National University School of Medicine, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea
3 shared publications - Jin-Woo Oh
Department of Nano Fusion Technology Pusan National University Busan 46241 Republic of Korea
3 shared publications - Su Jin Kim
Department of Internal Medicine, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8454
Late Delayed Bleeding After Gastric ESD with Esomeprazole/Sodium Bicarbonate Versus Conventional Esomeprazole, and Artificial Ulcer Healing with Esomeprazole/Sodium Bicarbonate: A Retrospective Cohort Study
Background/Objectives: Artificial ulcers after gastric endoscopic submucosal dissection (ESD) generally heal within 8 weeks with proton pump inhibitor (PPI) therapy; however, delayed bleeding remains a clinically relevant complication. Esomeprazole/sodium bicarbonate is an immediate-release PPI formulation; its role after ESD is unclear. Methods: This single-center retrospective study included 923 patients who underwent gastric ESD from July 2017 through December 2025. Late delayed bleeding, defined as bleeding after second-look endoscopy, was compared between patients receiving esomeprazole/sodium bicarbonate (n = 532) and conventional esomeprazole (n = 391) using Firth logistic regression adjusted for calendar period and clinical factors. Eight-week artificial ulcer healing was assessed descriptively only in the esomeprazole/sodium bicarbonate group (n = 527). Results: Late delayed bleeding occurred in 26/923 patients (2.8%): 16/532 (3.0%) in the esomeprazole/sodium bicarbonate group and 10/391 (2.6%) in the conventional esomeprazole group. PPI formulation was not associated with late delayed bleeding (adjusted OR 0.872; 95% CI 0.313–2.427). Submucosal fibrosis (adjusted OR 4.502; 95% CI 1.969–10.292), antiplatelet use (adjusted OR 3.620; 95% CI 1.617–8.103), and anticoagulant use (adjusted OR 6.783; 95% CI 1.323–34.770) were independently associated with bleeding. All 26 patients with bleeding were men; sex was therefore excluded from the model. Complete healing was observed in 510/527 patients (96.8%); ulcer diameter ≥ 40 mm was independently associated with incomplete healing (adjusted OR 7.114; 95% CI 2.664–18.998). Conclusions: No statistically significant difference in late delayed bleeding was detected between formulations, although a clinically meaningful difference cannot be excluded. Healing was assessed only in the esomeprazole/sodium bicarbonate group and could not be compared between formulations. Late delayed bleeding was associated with submucosal fibrosis and antithrombotic therapy.
- 30 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8454
Open AccessLate Delayed Bleeding After Gastric ESD with Esomeprazole/Sodium Bicarbonate Versus Conventional Esomeprazole, and Artificial Ulcer Healing with Esomeprazole/Sodium Bicarbonate: A Retrospective Cohort Study
Background/Objectives: Artificial ulcers after gastric endoscopic submucosal dissection (ESD) generally heal within 8 weeks with proton pump inhibitor (PPI) therapy; however, delayed bleeding remains a clinically relevant complication. Esomeprazole/sodium bicarbonate is an immediate-release PPI formulation; its role after ESD is unclear. Methods: This single-center retrospective study included 923 patients who underwent gastric ESD from July 2017 through December 2025. Late delayed bleeding, defined as bleeding after second-look endoscopy, was compared between patients receiving esomeprazole/sodium bicarbonate (n = 532) and conventional esomeprazole (n = 391) using Firth logistic regression adjusted for calendar period and clinical factors. Eight-week artificial ulcer healing was assessed descriptively only in the esomeprazole/sodium bicarbonate group (n = 527). Results: Late delayed bleeding occurred in 26/923 patients (2.8%): 16/532 (3.0%) in the esomeprazole/sodium bicarbonate group and 10/391 (2.6%) in the conventional esomeprazole group. PPI formulation was not associated with late delayed bleeding (adjusted OR 0.872; 95% CI 0.313–2.427). Submucosal fibrosis (adjusted OR 4.502; 95% CI 1.969–10.292), antiplatelet use (adjusted OR 3.620; 95% CI 1.617–8.103), and anticoagulant use (adjusted OR 6.783; 95% CI 1.323–34.770) were independently associated with bleeding. All 26 patients with bleeding were men; sex was therefore excluded from the model. Complete healing was observed in 510/527 patients (96.8%); ulcer diameter ≥ 40 mm was independently associated with incomplete healing (adjusted OR 7.114; 95% CI 2.664–18.998). Conclusions: No statistically significant difference in late delayed bleeding was detected between formulations, although a clinically meaningful difference cannot be excluded. Healing was assessed only in the esomeprazole/sodium bicarbonate group and could not be compared between formulations. Late delayed bleeding was associated with submucosal fibrosis and antithrombotic therapy.
- Open Access
- 28 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3357
Ilaprazole Versus Esomeprazole for Artificial Ulcer Healing After Gastric Endoscopic Submucosal Dissection: A Single-Center Retrospective Study
Background: Endoscopic submucosal dissection (ESD) is widely used for the treatment of gastric neoplasia; however, the large artificial ulcer created during the procedure requires several weeks to heal. Although proton pump inhibitors (PPIs) are routinely administered after ESD, evidence comparing individual PPIs for artificial ulcer healing in real-world practice remains limited. This study compared the effectiveness of oral ilaprazole and oral esomeprazole as maintenance therapy after gastric ESD. Methods: This retrospective single-center study included patients who underwent gastric ESD between January 2020 and December 2024. All patients received intravenous PPI therapy for two days after ESD and were subsequently prescribed either oral ilaprazole 20 mg once daily or esomeprazole 40 mg once daily for 8 weeks. The primary outcome was complete artificial ulcer healing at 8 weeks. The secondary outcome was post-discharge delayed bleeding. Results: A total of 229 patients were analyzed (147 in the esomeprazole group and 82 in the ilaprazole group). The overall 8-week ulcer healing rate was 94.3%, with no significant difference between the ilaprazole and esomeprazole groups (97.5% vs. 92.5%, p = 0.114). In multivariate analysis, artificial ulcer size ≥ 30 mm was the only independent predictor of incomplete ulcer healing (odds ratio 20.850, 95% confidence interval 1.884–230.712, p = 0.013). Post-discharge delayed bleeding occurred in 8 patients (3.4%), all in the esomeprazole group (p = 0.032). No treatment-related adverse events were observed. Conclusions: Ilaprazole demonstrated ulcer-healing efficacy comparable to esomeprazole after gastric ESD. Artificial ulcer size ≥ 30 mm was the principal determinant of delayed healing, whereas the treatment group was not independently associated with healing outcomes. Ilaprazole may be considered a reasonable maintenance PPI option in routine post-ESD management.
- 28 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3357
Open AccessIlaprazole Versus Esomeprazole for Artificial Ulcer Healing After Gastric Endoscopic Submucosal Dissection: A Single-Center Retrospective Study
Background: Endoscopic submucosal dissection (ESD) is widely used for the treatment of gastric neoplasia; however, the large artificial ulcer created during the procedure requires several weeks to heal. Although proton pump inhibitors (PPIs) are routinely administered after ESD, evidence comparing individual PPIs for artificial ulcer healing in real-world practice remains limited. This study compared the effectiveness of oral ilaprazole and oral esomeprazole as maintenance therapy after gastric ESD. Methods: This retrospective single-center study included patients who underwent gastric ESD between January 2020 and December 2024. All patients received intravenous PPI therapy for two days after ESD and were subsequently prescribed either oral ilaprazole 20 mg once daily or esomeprazole 40 mg once daily for 8 weeks. The primary outcome was complete artificial ulcer healing at 8 weeks. The secondary outcome was post-discharge delayed bleeding. Results: A total of 229 patients were analyzed (147 in the esomeprazole group and 82 in the ilaprazole group). The overall 8-week ulcer healing rate was 94.3%, with no significant difference between the ilaprazole and esomeprazole groups (97.5% vs. 92.5%, p = 0.114). In multivariate analysis, artificial ulcer size ≥ 30 mm was the only independent predictor of incomplete ulcer healing (odds ratio 20.850, 95% confidence interval 1.884–230.712, p = 0.013). Post-discharge delayed bleeding occurred in 8 patients (3.4%), all in the esomeprazole group (p = 0.032). No treatment-related adverse events were observed. Conclusions: Ilaprazole demonstrated ulcer-healing efficacy comparable to esomeprazole after gastric ESD. Artificial ulcer size ≥ 30 mm was the principal determinant of delayed healing, whereas the treatment group was not independently associated with healing outcomes. Ilaprazole may be considered a reasonable maintenance PPI option in routine post-ESD management.
- Open Access
- 31 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Anti-amoebic and biocompatible properties of nephrite-embedded contact lenses
Acanthamoeba keratitis remains a severe complication of contact lens (CL) wear, and preventing trophozoite adhesion to the lens surface is a critical step in preventing infection. This study investigated the anti-amoebic performance and ocular safety of soft CLs embedded with nephrite, a mineral with inherent antimicrobial activity. Clear, cosmetic, and nephrite-embedded CLs were compared. We uniformly dispersed nephrite powder onto the inner mold surface and encapsulated it within the polymer network using the Flusier method, preventing direct corneal exposure while maintaining transparency. In vitro assays demonstrated that nephrite-embedded CLs had significantly fewer adherent Acanthamoeba lugdunensis trophozoites than clear (p = 0.0093) and cosmetic CLs (p = 0.0068). SEM images showed reduced pseudopodia formation and round, contracted morphology of the attached trophozoites, suggesting early encystment. Although AFM revealed greater surface roughness than clear lenses, Acanthamoeba adhesion was still markedly lower. In vivo evaluation in rabbits showed no corneal opacity, no histologic inflammatory response, and no significant differences in corneal thickness or endothelial cell density compared with other groups. These findings indicate that the nephrite-embedded CLs developed in this study effectively inhibited Acanthamoeba adhesion while maintaining corneal safety, suggesting nephrite as a promising material for CLs with anti-amoebic properties.
- 31 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAnti-amoebic and biocompatible properties of nephrite-embedded contact lenses
Acanthamoeba keratitis remains a severe complication of contact lens (CL) wear, and preventing trophozoite adhesion to the lens surface is a critical step in preventing infection. This study investigated the anti-amoebic performance and ocular safety of soft CLs embedded with nephrite, a mineral with inherent antimicrobial activity. Clear, cosmetic, and nephrite-embedded CLs were compared. We uniformly dispersed nephrite powder onto the inner mold surface and encapsulated it within the polymer network using the Flusier method, preventing direct corneal exposure while maintaining transparency. In vitro assays demonstrated that nephrite-embedded CLs had significantly fewer adherent Acanthamoeba lugdunensis trophozoites than clear (p = 0.0093) and cosmetic CLs (p = 0.0068). SEM images showed reduced pseudopodia formation and round, contracted morphology of the attached trophozoites, suggesting early encystment. Although AFM revealed greater surface roughness than clear lenses, Acanthamoeba adhesion was still markedly lower. In vivo evaluation in rabbits showed no corneal opacity, no histologic inflammatory response, and no significant differences in corneal thickness or endothelial cell density compared with other groups. These findings indicate that the nephrite-embedded CLs developed in this study effectively inhibited Acanthamoeba adhesion while maintaining corneal safety, suggesting nephrite as a promising material for CLs with anti-amoebic properties.
- Open Access
Clinical Characteristics and Prognosis of Esophageal Squamous Cell Carcinoma in Patients Under 60 Years of Age
Background: Esophageal squamous cell carcinoma (ESCC) typically occurs in older individuals. The etiology and clinical characteristics of ESCC in relatively younger patients under 60 years of age remain unclear. Understanding whether age affects tumor behavior or prognosis is important for improving patient management. This study aimed to analyze the characteristics of ESCC diagnosed before the age of 60. Methods: We retrospectively reviewed the medical records of ESCC patients diagnosed between December 2008 and May 2025. A total of 516 patients were divided into two groups based on whether they were aged 60 or above. Medical history, clinical features, and outcomes were compared between the two groups. Results: There were 100 patients under 60 years and 416 patients aged 60 and above. The median ages were 55 (range 41–59) and 72 (range 60–95), respectively. Younger patients had a significantly stronger association with heavy drinking (72.0% vs. 39.2%, p < 0.001) and smoking (76.0% vs. 55.0%, p < 0.001). There was a trend toward more advanced disease (Stage IV: 26.0% vs. 18.5%, p = 0.094) and metastatic presentation (18.0% vs. 13.9%, p = 0.305) in the under-60 group. Despite being younger with better performance status and fewer comorbidities, their overall survival did not differ from that of older patients (HR 0.92; 95% CI, 0.67–1.26; p = 0.593). Conclusions: Patients diagnosed with ESCC under the age of 60 showed a stronger association with heavy alcohol consumption and smoking and more frequent presentation with advanced-stage disease compared with older patients. Younger age did not confer a better prognosis, highlighting the importance of early detection and timely intervention regardless of patient age.
Open AccessClinical Characteristics and Prognosis of Esophageal Squamous Cell Carcinoma in Patients Under 60 Years of Age
Background: Esophageal squamous cell carcinoma (ESCC) typically occurs in older individuals. The etiology and clinical characteristics of ESCC in relatively younger patients under 60 years of age remain unclear. Understanding whether age affects tumor behavior or prognosis is important for improving patient management. This study aimed to analyze the characteristics of ESCC diagnosed before the age of 60. Methods: We retrospectively reviewed the medical records of ESCC patients diagnosed between December 2008 and May 2025. A total of 516 patients were divided into two groups based on whether they were aged 60 or above. Medical history, clinical features, and outcomes were compared between the two groups. Results: There were 100 patients under 60 years and 416 patients aged 60 and above. The median ages were 55 (range 41–59) and 72 (range 60–95), respectively. Younger patients had a significantly stronger association with heavy drinking (72.0% vs. 39.2%, p < 0.001) and smoking (76.0% vs. 55.0%, p < 0.001). There was a trend toward more advanced disease (Stage IV: 26.0% vs. 18.5%, p = 0.094) and metastatic presentation (18.0% vs. 13.9%, p = 0.305) in the under-60 group. Despite being younger with better performance status and fewer comorbidities, their overall survival did not differ from that of older patients (HR 0.92; 95% CI, 0.67–1.26; p = 0.593). Conclusions: Patients diagnosed with ESCC under the age of 60 showed a stronger association with heavy alcohol consumption and smoking and more frequent presentation with advanced-stage disease compared with older patients. Younger age did not confer a better prognosis, highlighting the importance of early detection and timely intervention regardless of patient age.
- 16 November 2023
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 246, 115838
Non-intrusive quality appraisal of differentiation-induced cardiovascular stem cells using E-Nose sensor technology
- 16 November 2023
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 246, 115838
Non-intrusive quality appraisal of differentiation-induced cardiovascular stem cells using E-Nose sensor technology
- Open Access
- 23 October 2023
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 244, 115780
3D superstructure based metabolite profiling for glaucoma diagnosis
- 23 October 2023
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 244, 115780
Open Access3D superstructure based metabolite profiling for glaucoma diagnosis